HHS, Cohen Foundation Award $1M to Lyme Disease Dx Research Projects
The funding is being provided to 10 groups through the LymeX Diagnostics Prize initiative, which was launched in late 2020 by theHHS- and Cohen Foundation-backed Lyme Innovation Accelerator.
Adaptive Biotechnologies Halts T-Detect Commercialization, Reports 13 Percent Q2 Revenue Growth
The company realized it is costly to develop single-disease T-Detect assays and is deferring commercialization until a clear path to reimbursement is proven.
Although it has seemingly tried to do everything, everywhere, all at once with its immune sequencing technology, Adaptive has sharpened its focus.
The Seattle-based company recently completed a strategic reorganization around its two major business areas by cutting the workforce and appointing a new CFO.
Adaptive Biotechnologies to Focus on Immune Medicine, Minimal Residual Disease Testing Businesses
The Seattle-based company said this week that its immune medicine and minimal residual disease testing business arms will drive the firm's future growth.